Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 1, 2006, Pages 19-22

  Rogowski, Ori ^a   Shapira, Itzhak ^a   Assayag, Einor Ben ^a,b,c   Bornstein, Nathan M ^b,c   Toker, Sharon ^a,c   Melamed, Samuel ^c,d   Shirom, Arie ^c   Berliner, Shlomo ^b,c  

^a Institute for Special Medical Examinations (MALRAM)   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d Occupational Health and Rehabilitation Institute Israel   (Israel)

Author keywords

Aspirin; Atherothrombosis; C reactive protein

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GENDER; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MODULATION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SMOKING; THROMBOSIS; VASCULAR DISEASE;

EID: 31644451876     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000198050.27387.ea     Document Type: Article

References (19)

1. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004; 25:1197-1207.
2. Ridker PM. Cardiology patient page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation 2003; 108:e81-e85.
3. Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 2004; 117:499-507.
4. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al., the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
5. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
6. Rogowski O, Toker S, Shapira I, Melamed S, Shirom A, Zeltser D, Berliner S. Values of high sensitivity C-reactive protein in each month of the year in apparently healthy individuals. Am J Cardiol 2005; 95:152-155.
7. Berliner S, Rogowski O, Aharonov S, Mardi T, Tolshinsky T, Rozenblat M, et al. Erythrocyte adhesiveness/aggregation. A novel biomarker for the detection of low grade internal inflammation in individuals with atherothrombotic risk factors and proven, vascular disease. Am Heart J 2005; 149:260-267.
8. Rogowski O, Shapira I, Zimran A, Zeltser D, Elstein D, Attias D, et al. Automated system to detect low-grade underlying inflammatory profile: Gaucher disease as a model. Blood Cells Mol Dis 2005; 34:26-29.
9. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45:2136-2141.
10. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321:129-135.
11. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased pro-inflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100:793-798.
12. Solheim S, Arnesen H, Eikvar L, Hurlen M, Seljeflot I. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol 2003; 92:843-845.
13. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001; 37:2036-2041.
14. Feng D, Tracy RP, Lipinska I, Murillo J, McKenna C, Tofler GH. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis 2000; 9:37-41.
15. Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003; 169:155-158.
16. Joynt KE, Gattis WA, Hasselblad V, Fuzaylov SY, Serebruany VL, Gurbel PA, et al. Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol 2004; 93:783-785.
17. Azar RR, Klayme S, Germanos M, Kassab R, Tawm S, Aboujaoude S, Naman R. Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Am J Cardiol 2003; 92:236-239.
18. Kim SB, Lee SK, Min WK, Chi HS, Park JS. Lack of effects of low-dose aspirin on high-sensitivity C-reactive protein, hemostatic factors, and troponin T in CAPD patients. Perit Dial Int 2002; 22:721-723.
19. Mozaffarian D, Pischon T, Hankinson SE, Rifai N, Joshipura K, Willett WC, Rimm EB. Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr 2004; 79:606-612.